About Us
Epion Therapeutics is developing a minimally invasive treatment for ectatic corneal disease that can bring early intervention to millions of patients globally. Our EpiSmart approach is a transformative cross-linking system designed to treat keratoconus without disrupting the epithelium, allowing for a rapid return to normal activities.
Epion’s elegant approach elevates the current standard of care for keratoconus by enabling the treatment of both eyes simultaneously and eliminating the need for further deterioration. EpiSmart, Epion’s transformative cross-linking system, is a true epithelium on approach that does not disrupt the epithelium. Epion is striving to deliver safer and more accessible vision-preserving care to millions of patients globally.
Meet our team
Epion was founded and is supported by experts in the field, including Michael W. Belin, MD, Chief Medical Officer, who developed the Belin ABCD Progression Display which is able to identify keratoconus progression earlier than previously relied upon metrics.
Have questions?
Get in touch with a Epion representative today.